High expression of ID family and IGJ genes signature as predictor of low induction treatment response and worst survival in adult Hispanic patients with B-acute lymphoblastic leukemia.
High expression of ID family and IGJ genes signature as predictor of low induction treatment response and worst survival in adult Hispanic patients with B-acute lymphoblastic leukemia.
复制标题
DOI：
10.1186/s13046-016-0333-z
复制
发表时间：
2016-04-05
期刊：
影响因子：
--
通讯作者：
Zabaleta J
中科院分区：
文献类型：
--
作者：
Cruz-Rodriguez N;Combita AL;Enciso LJ;Quijano SM;Pinzon PL;Lozano OC;Castillo JS;Li L;Bareño J;Cardozo C;Solano J;Herrera MV;Cudris J;Zabaleta J
B-急性淋巴细胞白血病（B-ALL）是一种血液系统恶性肿瘤，成人患者的临床结果较差，生存率较低。与其他种族群体相比，西班牙裔人群的缓解率几乎低 30%，总生存期 (OS) 低近两年。只有 61% 的哥伦比亚成年 ALL 患者达到完全缓解 (CR)，中位总生存期为 11.3 个月，无事件生存期 (EFS) 为 7.34 个月。识别预后因素对于应用正确的治疗策略以及随后获得成功的结果至关重要。我们的目标是确定可能与治疗反应相关的基因表达特征，并评估其作为西班牙裔患者预后工具的效用。我们纳入了 43 名新诊断为 B-ALL 的成年患者。我们使用微阵列分析来识别通过差异基因表达分析区分治疗反应差和良好的基因。通过实时 PCR (RT-PCT) 验证表达谱。我们鉴定了诱导治疗有反应者和无反应者之间的 442 个差异表达基因。根据 7 个基因特征表达的分层分析揭示了 2 个临床特征和结果不同的患者亚群。我们的研究表明，西班牙裔患者对诱导治疗的反应和临床结果可以从疾病发作时预测，并且基因表达谱可用于充分、准确地对患者风险进行分层。本研究首次展示了哥伦比亚 B-ALL 成人的基因表达谱及其与疾病早期分层的相关性。本文的在线版本 (doi:10.1186/s13046-016-0333-z) 包含补充材料，可供授权用户使用。
B-Acute lymphoblastic leukemia (B-ALL) represents a hematologic malignancy with poor clinical outcome and low survival rates in adult patients. Remission rates in Hispanic population are almost 30 % lower and Overall Survival (OS) nearly two years inferior than those reported in other ethnic groups. Only 61 % of Colombian adult patients with ALL achieve complete remission (CR), median overall survival is 11.3 months and event-free survival (EFS) is 7.34 months. Identification of prognostic factors is crucial for the application of proper treatment strategies and subsequently for successful outcome. Our goal was to identify a gene expression signature that might correlate with response to therapy and evaluate the utility of these as prognostic tool in hispanic patients. We included 43 adult patients newly diagnosed with B-ALL. We used microarray analysis in order to identify genes that distinguish poor from good response to treatment using differential gene expression analysis. The expression profile was validated by real-time PCR (RT-PCT). We identified 442 differentially expressed genes between responders and non-responders to induction treatment. Hierarchical analysis according to the expression of a 7-gene signature revealed 2 subsets of patients that differed in their clinical characteristics and outcome. Our study suggests that response to induction treatment and clinical outcome of Hispanic patients can be predicted from the onset of the disease and that gene expression profiles can be used to stratify patient risk adequately and accurately. The present study represents the first that shows the gene expression profiling of B-ALL Colombian adults and its relevance for stratification in the early course of disease. The online version of this article (doi:10.1186/s13046-016-0333-z) contains supplementary material, which is available to authorized users.